OBJECTIVE: To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity. DESIGN: Randomized, double-blind, multicenter, placebo-controlled study. SETTING: Eight centers across Belgium, France, and Switzerland. PARTICIPANTS: Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed onoral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled. INTERVENTION: Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo. MAIN OUTCOME MEASURES: I-QOL questionnaire completed at screening and over a 24-week post-treatment period. RESULTS: The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points. CONCLUSIONS: Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
RCT Entities:
OBJECTIVE: To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity. DESIGN: Randomized, double-blind, multicenter, placebo-controlled study. SETTING: Eight centers across Belgium, France, and Switzerland. PARTICIPANTS: Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled. INTERVENTION: Single dose of botulinum toxin type A (Botox) (200 or 300 U) or placebo. MAIN OUTCOME MEASURES: I-QOL questionnaire completed at screening and over a 24-week post-treatment period. RESULTS: The Cronbach alpha ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinencepatients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points. CONCLUSIONS: Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
Authors: Blayne Welk; Sara Lenherr; Sean Elliott; John Stoffel; Angela P Presson; Chong Zhang; Jeremy B Myers Journal: Spinal Cord Date: 2017-11-29 Impact factor: 2.772
Authors: William Hollingworth; Jonathan D Campbell; Jonathan Kowalski; Arliene Ravelo; Isabelle Girod; Andrew Briggs; Sean D Sullivan Journal: Qual Life Res Date: 2010-01-22 Impact factor: 4.147
Authors: Michael B Chancellor; Vaishali Patel; Wendy W Leng; Patrick J Shenot; Wayne Lam; Denise R Globe; Alex L Loeb; Christopher R Chapple Journal: Neurology Date: 2013-07-26 Impact factor: 9.910
Authors: Nacho Castejón; Kristin Khalaf; Quanhong Ni; Jesús Cuervo; Donald L Patrick Journal: Health Qual Life Outcomes Date: 2015-08-01 Impact factor: 3.186
Authors: Jonathan D Campbell; Katharine S Gries; Jonathan H Watanabe; Arliene Ravelo; Roger R Dmochowski; Sean D Sullivan Journal: BMC Urol Date: 2009-11-20 Impact factor: 2.264